All Stories

  1. One-Year Progression of Speech, Drooling and Swallowing in Parkinson's Disease
  2. RAGE Against the Glycation Machine in Synucleinopathies: Time to Explore New Questions
  3. miR-101a-3p Impairs Synaptic Plasticity and Contributes to Synucleinopathy
  4. Molecular Mechanisms Mediating the Transfer of Disease-Associated Proteins and Effects on Neuronal Activity
  5. Alpha-Synuclein Glycation and the Action of Anti-Diabetic Agents in Parkinson’s Disease
  6. α-Synuclein interacts with the switch region of Rab8a in a Ser129 phosphorylation-dependent manner
  7. Linking alpha-synuclein phosphorylation to reactive oxygen species formation and mitochondrial dysfunction in SH-SY5Y cells
  8. Protein phosphorylation in neurodegeneration: friend or foe?
  9. Phosphorylation Modulates Clearance of Alpha-Synuclein Inclusions in a Yeast Model of Parkinson's Disease
  10. Challenges and Promises in the Development of Neurotrophic Factor-Based Therapies for Parkinson’s Disease
  11. Modulation of alpha-synuclein toxicity in yeast using a novel microfluidic-based gradient generator
  12. Studying the Molecular Determinants of Protein Oligomerization in Neurodegenerative Disorders by Bimolecular Fluorescence Complementation
  13. MeCP2: a novel Huntingtin interactor
  14. Off-pathwayα-synuclein oligomers seem to alterα-synuclein turnover in a cell model but lack seeding capabilityin vivo
  15. The NAD-dependent deacetylase sirtuin 2 is a suppressor of microglial activation and brain inflammation
  16. Inhibition of formation of α-synuclein inclusions by mannosylglycerate in a yeast model of Parkinson's disease
  17. P4–053: Alpha‐synuclein oligomers can act as seed in a fibrillation assay but do not cause increased aggregation in living cells
  18. β-synuclein aggregates and induces neurodegeneration in dopaminergic neurons
  19. PLK2 Modulates α-Synuclein Aggregation in Yeast and Mammalian Cells
  20. Harnessing the power of yeast to unravel the molecular basis of neurodegeneration
  21. The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease
  22. alpha-Synuclein and intracellular trafficking: impact on the spreading of Parkinson’s disease pathology
  23. Heat-mediated enrichment of α-synuclein from cells and tissue for assessing post-translational modifications
  24. Crystal Structure of kynurenine 3-monooxygenase - truncated at position 394 plus HIS tag cleaved.
  25. Cocrystal Structure of kynurenine 3-monooxygenase in complex with UPF 648 inhibitor(KMO-394UPF)
  26. Crystal Structure of kynurenine 3-monooxygenase (KMO-394)
  27. Crystal Structure of kynurenine 3-monooxygenase (KMO-396Prot)
  28. Crystal Structure of kynurenine 3-monooxygenase (KMO-396Prot-Se)
  29. Structural basis of kynurenine 3-monooxygenase inhibition
  30. Oxidative and nitrative alpha-synuclein modifications and proteostatic stress: implications for disease mechanisms and interventions in synucleinopathies
  31. Live-cell imaging of p53 interactions using a novel Venus-based bimolecular fluorescence complementation system
  32. SIRT1 and SIRT2: emerging targets in neurodegeneration
  33. Assessing the Subcellular Dynamics of Alpha-synuclein Using Photoactivation Microscopy
  34. Impairment of the septal cholinergic neurons in MPTP-treated A30P α-synuclein mice
  35. Sirtuins in Biology and Disease
  36. The zebrafish homologue of Parkinson's disease ATP13A2 is essential for embryonic survival
  37. LRRK2 interactions with α-synuclein in Parkinson’s disease brains and in cell models
  38. Parkinson’s disease-associated mutations in DJ-1 modulate its dimerization in living cells
  39. SNCA (α-synuclein)-induced toxicity in yeast cells is dependent on Sir2-mediated mitophagy
  40. Epigenetic regulation of BACE1 in Alzheimer’s disease patients and in transgenic mice
  41. B10 The role of n-terminal phosphorylation in huntingtin's oligomerisation, aggregation and toxicity
  42. Epigenetics in Parkinson’s and Alzheimer’s Diseases
  43. Impaired TrkB receptor signaling contributes to memory impairment in APP/PS1 mice
  44. Highlights of the Keystone Symposium: sirtuins in metabolism, aging and disease
  45. Novel Molecular Therapeutics in Parkinson's Disease
  46. High-throughput study of alpha-synuclein expression in yeast using microfluidics for control of local cellular microenvironment
  47. Editorial on Special Topic: Sirtuins in Metabolism, Aging, and Disease
  48. SIRT2 as a Therapeutic Target for Age-Related Disorders
  49. Imaging Protein Oligomerization in Neurodegeneration Using Bimolecular Fluorescence Complementation
  50. Idebenone and Resveratrol Extend Lifespan and Improve Motor Function of HtrA2 Knockout Mice
  51. Synthesis and in vitro evaluation of fluorinated styryl benzazoles as amyloid-probes
  52. α-Synuclein modifies huntingtin aggregation in living cells
  53. Dopamine-depletion and increased α-synuclein load induce degeneration of cortical cholinergic fibers in mice
  54. Antibodies against Alpha-Synuclein Reduce Oligomerization in Living Cells
  55. Tau Enhances α-Synuclein Aggregation and Toxicity in Cellular Models of Synucleinopathy
  56. Convergence of miRNA Expression Profiling, α-Synuclein Interacton and GWAS in Parkinson's Disease
  57. Aggresome formation and segregation of inclusions influence toxicity of α-synuclein and synphilin-1 in yeast
  58. FlAsH illuminates Aβ aggregation
  59. Impaired Proteostasis Contributes to Renal Tubular Dysgenesis
  60. Assessment of the Efficacy of Solutes from Extremophiles on Protein Aggregation in Cell Models of Huntington’s and Parkinson’s Diseases
  61. Epigenetics in neurodegeneration: A new layer of complexity
  62. Visualization of cell-to-cell transmission of mutant huntingtin oligomers
  63. α-Synuclein propagates from mouse brain to grafted dopaminergic neurons and seeds aggregation in cultured human cells
  64. Editorial [Hot Topic: Drug Discovery for CNS Disorders: From Bench to Bedside (Guest Editor: Tiago Fleming Outeiro)]
  65. Neurotrophic Factors as a Protective Strategy in Parkinsons Disease
  66. Simple is good: yeast models of neurodegeneration
  67. Zooming into protein oligomerization in neurodegeneration using BiFC
  68. Synphilin-1 Enhances α-Synuclein Aggregation in Yeast and Contributes to Cellular Stress and Cell Death in a Sir2-Dependent Manner
  69. Sirtuins: Common Targets in Aging and in Neurodegeneration
  70. Synaptic Dysfunction in Parkinson’s Disease: From Protein Misfolding to Functional Alterations
  71. A non-invasive method based on saliva to characterize transthyretin in familial amyloidotic polyneuropathy patients using FT-ICR high-resolution MS
  72. Increased serum HSP70 levels are associated with the duration of diabetes
  73. The sour side of neurodegenerative disorders: the effects of protein glycation
  74. Current and Future Therapeutic Strategies for Parkinsons Disease
  75. P3.009 Aging and neurodegeneration: common targets, common hopes
  76. Dopamine-Induced Conformational Changes in Alpha-Synuclein
  77. Novel insights into alpha syynuclein intracellular dynamics
  78. Dopamine-Induced Conformational Changes in a-Synuclein
  79. Unraveling the role of A-synuclein phosphorylation in the etiology of parkinson's disease
  80. Direct quantification of CSF α-synuclein by ELISA and first cross-sectional study in patients with neurodegeneration
  81. From Mad Cows to Neurotic Yeast: Novel Molecular Approaches to Understand Neurodegeneration
  82. Therapeutic role of sirtuins in neurodegenerative disease
  83. Correction: Formation of Toxic Oligomeric α-Synuclein Species in Living Cells
  84. CHIP Targets Toxic  -Synuclein Oligomers for Degradation
  85. Formation of Toxic Oligomeric α-Synuclein Species in Living Cells
  86. Yeast as a model for studying human neurodegenerative disorders
  87. Yeast as a model for studying human neurodegenerative disorders
  88. Detection of Compounds That Rescue Rab1‐Synuclein Toxicity
  89. Angiotensin II protects against α-synuclein toxicity and reduces protein aggregation in vitro
  90. Pharmacological inhibition of PARP-1 reduces α-synuclein- and MPP+-induced cytotoxicity in Parkinson’s disease in vitro models
  91. Mechanisms of Disease II: Cellular Protein Quality Control
  92. Dopaminergic neuron loss and up-regulation of chaperone protein mRNA induced by targeted over-expression of alpha-synuclein in mouse substantia nigra
  93. Protein Aggregation Disorders
  94. Small heat shock proteins protect against α-synuclein-induced toxicity and aggregation
  95. Yeast as a drug discovery platform in Huntington's and Parkinson's diseases
  96. Stress Tolerance, Metabolism, and Development
  97. Yeast Cells as a Discovery Platform for Neurodegenerative Disease
  98. Molecular Genetics Approaches in Yeast to Study Amyloid Diseases
  99. Interactions Among α-Synuclein, Dopamine, and Biomembranes: Some Clues for Understanding Neurodegeneration in Parkinson's Disease
  100. Yeast Cells Provide Insight into Alpha-Synuclein Biology and Pathobiology
  101. Prion protein gene polymorphisms in Saccharomyces cerevisiae